• Adnan I Qureshi, Kimberley Pfeiffer, Sehar Babar, Wei Huang, Iryna Lobanova, Muhammad F Ishfaq, Brandi R French, Farhan Siddiq, and Camilo R Gomez.
• Department of Neurology, University of Missouri, Columbia, Missouri, USA.
• J Neuroimaging. 2021 Nov 1; 31 (6): 1126-1134.

Background And PurposeWe report the results of intra-arterial injection of lidocaine in the middle meningeal artery in patients with intractable headache or status migrainosus.MethodsWe treated four patients with intra-arterial lidocaine (2 mg/ml) in doses up to 50 mg in each middle meningeal artery via a microcatheter bilaterally (except in one patient). In two patients with intractable headache, the daily maximum intensity of headache (graded by 11-point numeric rating scale) was recorded for 7 days postprocedure. In two patients with status migrainosus, migraine-related disability 3 months prior and after treatment using MIDAS (Migraine Disability Assessment) questionnaire was recorded.ResultsIntra-arterial lidocaine reduced the headache intensity from 8/10 and 10/10 to 0/10 in the two patients with intractable headaches for 2 days (day 0 and day 1) postprocedure. Despite recurrence of headache on day 2, the intensity was less than preprocedure intensity up to the last day recorded (by 3 and 2 points on day 7). In the two patients with status migrainosus, there was immediate reduction in headache intensity following intra-arterial lidocaine. The post treatment 3-month MIDAS score was lower in both patients compared with pretreatment 3-month score; 3 versus 30 and 55 versus 90. Severe disability preprocedure by MIDAS was reduced to little or no disability postprocedure in one patient.ConclusionsIntra-arterial lidocaine resulted in amelioration of headache in patients with intractable headache and those with status migrainosus with improvement lasting longer than the short half-life of lidocaine possibly related to central desensitization.© 2021 American Society of Neuroimaging.

19 keywords...

hide…